Chemotherapy
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Journal of Clinical Oncology 2023 April 20 [Link] Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti Abstract Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months,…
Read MoreEpidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database
Cancer Medicine 2023 April 16 [Link] Patrick Bou-Samra, Austin Chang, Feredun Azari, Gregory Kennedy, Alix Segil, Emily Guo, Melina Marmarelis, Corey Langer, Sunil Singhal Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer of the cells lining the pleural cavity with a low overall incidence. The National Cancer Database (NCDB) released in August 2022…
Read MoreOne Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…
Read MoreImmunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?
Journal of Clinical Medicine 2023 March 27 [Link] Xiaotong Guo, Lede Lin, Jiang Zhu Abstract (1) Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor arising from the pleural surface. For relapsed MPM, there is no accepted standard of- are for subsequent treatment. Thus, we aimed to compare the efficacy of chemotherapy, targeting…
Read MoreExcess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Frontiers in Immunology 2023 March 24 [Link] Mégane Willems, Arnaud Scherpereel, Eric Wasielewski, Jo Raskin, Hélène Brossel, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Majeed Jamakhani, Vincent Heinen, Renaud Louis, Bernard Duysinx, Malik Hamaidia, Luc Willems Abstract Background: Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the…
Read MoreDisparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma
JAMA Network Open 2023 March 1 [Link] Ahmed Alnajar, Samuel A Kareff, Syed S Razi, J Sunil Rao, Gilberto De Lima Lopes, Dao M Nguyen, Nestor Villamizar, Estelamari Rodriguez Abstract Importance: Outcomes of localized malignant pleural mesothelioma (MPM) remain poor despite multimodality therapy. It is unclear what role disparities have in the overall survival (OS)…
Read MoreMalignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis
Journal of Surgical Oncology 2023 March 18 [Link] Emanuela Taioli, Andrea Wolf, Naomi Alpert, Daniel Rosenthal, Raja Flores Abstract Background: Pleural mesothelioma is rare cancer linked to asbestos exposure. Previous research has indicated that female individuals have better survival than male individuals, but this has never been examined in the Surveillance, Epidemiology, and End Results…
Read MoreBenefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
Cancers 2023 February 28 [Link] Mhd Ouis Al Khatib, Giulia Pinton, Laura Moro, Chiara Porta Abstract Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer that is mainly associated with prior exposure to asbestos fibers. Despite being a rare cancer, its global rate is increasing and the prognosis remains extremely poor. Over the last two…
Read MoreThe Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2023 February 22 [Link] Maxime Borgeaud, Floryane Kim, Alex Friedlaender, Filippo Lococo, Alfredo Addeo, Fabrizio Minervini Abstract Malignant pleural mesothelioma (MPM) is a rare cancer usually caused by asbestos exposure and associated with a very poor prognosis. After more than a decade without new therapeutic options, immune checkpoint inhibitors (ICIs) demonstrated…
Read MoreLong-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
Case Reports in Medicine 2023 February 28 [Link] Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo Abstract A 76-year-old woman presented with lower abdominal pain and nausea and was referred to the gastroenterology department in our institution. Previous contrast-enhanced computed tomography (CE-CT) for…
Read More